ARTICLE

NANOTECHNOLOGICAL APPROACH TOWARDS ANTIVIRAL THERAPY

  1. HOME
  2. ARTICLE

02 Pages : 12-20

http://dx.doi.org/10.31703/giidr.2016(I-I).02      10.31703/giidr.2016(I-I).02      Published : Dec 2016

Nano-Technological Approach towards Anti-Viral Therapy

Abstract

    With time viral infections are increasing day by day due to various reasons like new viruses, the resistance of viruses to antiviral therapy, and mutation of one form of the virus to another form; these types of problems create many challenges in the field of research. Furthermore, a lot of challenges are encountered in the treatment of antiviral therapy, like interaction with other medication and use of increased frequency and a high dose of antiviral due to infection in CNS or synovial fluid where drug permeation is less. Consequently, toxicity and other side effect chances will be more. Nano-technological approaches are used to overcome these challenges. The beneficial properties come from such engineering, including stimuli sensitivity, targetability, and longevity; these are all combined to give multifunctional nano-carriers that concurrently execute different beneficial tasks

    Antiviral Therapy, Nano-Technology, Nano-Carriers, Nanoparticulate, and Nanomedicines

    (1) Mubashar Rehman
    Assistant Professor, Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan. (Corresponding Author)
    (2) Abdullah
    Undergraduate Student, Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.
    (3) Hassan Gul
    Undergraduate Student, Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.
    (4) Abid Ul Haq
    Undergraduate Student, Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.
Fulltext PDF

References

  • Adalja, A., & Inglesby, T. (2019). Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool. Expert Review of Anti-Infective Therapy, 17(7), 467-470
  • Alexaki, A., Liu, Y., & Wigdahl, B. (2008). Cellular Reservoirs of HIV-1 and their Role in Viral Persistence. Current HIV Research, 6(5), 388-400.
  • Amidon, G., Lennernäs, H., Shah, V., & Crison, J. (1995). Journal search results - Cite This for Me. Pharmaceutical Research, 12(3), 413- 420
  • Arshady, R., & Kono, K. (Eds.). (2006). Smart nano- particles in nano-medicine. Kentus
  • Baram-Pinto, D., Shukla, S., Perkas, N., Gedanken, A., & Sarid, R. (2009). Inhibition of Herpes Simplex Virus Type 1 Infection by Silver Nanoparticles Capped with Mercaptoethane Sulfonate. Bioconjugate Chemistry, 20(8), 1497-1502
  • Baron, B., Baron, R., & Baron, J. (2015). Repression of the Pontin (RUVBL1, TIP49) Gene by BCL6: Implications for the Pathogenesis of Human B and T Cell Lymphomas. Blood, 126(23), 4821-4821
  • Blecher, K., Nasir, A., & Friedman, A. (2011). The growing role of nano-technology in combating infectious disease. Virulence, 2(5), 395-40
  • Bule, M., Khan, F., & Niaz, K. (2019). Antivirals: Past, Present and Future. In Recent Advances in Animal Virology (pp. 425-446). Springer, Singapore
  • Chan, L., Lowes, S., & Hirst, B. (2004). The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. European Journal of Pharmaceutical Sciences, 21(1), 25-51
  • Chaudhuri, A., & Kennedy, P. G. E. (2002). Diagnosis and treatment of viral encephalitis. Postgraduate medical journal, 78(924), 575-583
  • Cojocaru, F., Botezat, D., Gardikiotis, I., Uritu, C., Dodi, G., & Trandafir, L. et al. (2020). Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers. Pharmaceutics, 12(2), 171
  • DeVincenzo, J., Whitley, R., Mackman, R., Scaglioni- Weinlich, C., Harrison, L., & Farrell, E. et al. (2014). Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study. New England Journal of Medicine, 371(8), 711-722.
  • Gerber, J. (2000). Using Pharmacokinetics to Optimize Antiretroviral Drug-Drug Interactions in the Treatment of Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 30(Supplement_2), S123-S129
  • Henahan, S. (1998). Fomivirsen focuses on the future in CMV retinitis. Inpharma Weekly, &NA;(1138), 11-12.
  • Hillaireau, H., & Couvreur, P. (2009). Nano-carriers' entry into the cell: relevance to drug delivery. Cellular and Molecular Life Sciences, 66(17), 2873-2896
  • Ketzinel-Gilad, M., Shaul, Y., & Galun, E. (2006). RNA interference for antiviral therapy. The Journal of Gene Medicine, 8(8), 933-950
  • Lara, H., Garza-Treviño, E., Ixtepan-Turrent, L., & Singh, D. (2011). Silver nano-particles are broad-spectrum bactericidal and virucidal compounds. Journal of Nanobiotechnology, 9(1), 30.
  • Liaw, Y. (2005). The current management of HBV drug resistance. Journal of Clinical Virology, 34, S143-S146
  • Mao, J., Wang, J., Chinchar, G., & Chinchar, V. (1999). Molecular characterization of a ranavirus isolated from largemouth bass Micropterus salmoides. Diseases of Aquatic Organisms, 37, 107-114
  • Milroy, D., & Featherstone, J. (2002). Antiviral market overview. Nature Reviews Drug Discovery, 1(1), 11-12
  • Mishra, B., Patel, B., & Tiwari, S. (2010). Colloidal nano-carriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine: Nano-technology, Biology and Medicine, 6(1), 9-24.
  • Ocadiz-Delgado, R., Albino-Sanchez, M., Garcia- Villa, E., Aguilar-Gonzalez, M., Cabello, C., & Rosete, D. et al. (2013). In situ molecular identification of the Influenza A (H1N1) 2009 Neuraminidase in patients with severe and fatal infections during a pandemic in Mexico City. BMC Infectious Diseases, 13(1).
  • Oshikoya, K., Ogunleye, Lawal, Senbanjo, S., & Oreagba. (2013). Clinically significant interactions between anti-retroviral and co-prescribed drugs for HIV-infected children: profiling and comparison of two drug databases. Therapeutics and Clinical Risk Management, 215
  • Riehemann, K., Schneider, S., Luger, T., Godin, B., Ferrari, M., & Fuchs, H. (2009). Nanomedicine-Challenge and Perspectives. Angewandte Chemie International Edition, 48(5), 872-897.
  • Rouse, B., & Sehrawat, S. (2010). Immunity and immunopathology to viruses: what decides the outcome Nature Reviews Immunology, 10(7), 514-526
  • Strasfeld, L., & Chou, S. (2010). Antiviral Drug Resistance: Mechanisms and Clinical Implications. Infectious Disease Clinics of North America, 24(2), 413-437
  • Singh, R., & Lillard, J. (2009). Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology, 86(3), 215-223.
  • Sharma, P., & Garg, S. (2010). Pure drug and polymer based nano-technologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Advanced Drug Delivery Reviews, 62(4-5), 491-502.
  • Sosnik, A., & Amiji, M. (2010). Nano-technology solutions for infectious diseases in developing nations. Advanced Drug Delivery Reviews, 62(4-5), 375-377
  • Torchilin, V. (2009). Multifunctional and stimuli sensitive pharmaceutical nano- carriers. European Journal of Pharmaceutics and Biopharmaceutics, 71(3), 431-444
  • Torchilin, V. (2009). Multifunctional and stimuli- sensitive pharmaceutical nano- carriers. European Journal of Pharmaceutics and Biopharmaceutics, 71(3), 431-444.
  • Vyas, S., Subhedar, R., & Jain, S. (2006). Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. Journal of Pharmacy and Pharmacology, 58(3), 321-326.
  • Villanueva-Flores, F., Castro-Lugo, A., Ramírez, O., & Palomares, L. (2020). Understanding cellular interactions with nanomaterials: towards a rational design of medical nanodevices. Nano-technology, 31(13), 132002
  • Williams, G., & Sinko, P. (1999). Oral absorption of the HIV protease inhibitors: a current update. Advanced Drug Delivery Reviews, 39(1-3), 211-238
  • Wong, H., Chattopadhyay, N., Wu, X., & Bendayan, R. (2010). Nano-technology applications for improved delivery of anti-retroviral drugs to the brain. Advanced Drug Delivery Reviews, 62(4-5), 503-517
  • Tiemann, K., & Rossi, J. (2009). RNAi-based therapeutics-current status, challenges and prospects. EMBO Molecular Medicine, 1(3), 142-151. doi: 10.1002/emmm.200900023

Cite this article

APA

CHICAGO

    CHICAGO : Rehman, Mubashar, Abdullah, and Hassan Gul. 2016. "Nano-Technological Approach towards Anti-Viral Therapy." Global Immunological & Infectious Diseases Review, I (I): 12-20 doi: 10.31703/giidr.2016(I-I).02

HARVARD

    HARVARD : REHMAN, M., ABDULLAH. & GUL, H. 2016. Nano-Technological Approach towards Anti-Viral Therapy. Global Immunological & Infectious Diseases Review, I, 12-20.

MHRA

    MHRA : Rehman, Mubashar, Abdullah, and Hassan Gul. 2016. "Nano-Technological Approach towards Anti-Viral Therapy." Global Immunological & Infectious Diseases Review, I: 12-20

MLA

    MLA : Rehman, Mubashar, Abdullah, and Hassan Gul. "Nano-Technological Approach towards Anti-Viral Therapy." Global Immunological & Infectious Diseases Review, I.I (2016): 12-20 Print.

OXFORD

    OXFORD : Rehman, Mubashar, Abdullah, , and Gul, Hassan (2016), "Nano-Technological Approach towards Anti-Viral Therapy", Global Immunological & Infectious Diseases Review, I (I), 12-20

TURABIAN

    TURABIAN : Rehman, Mubashar, Abdullah, and Hassan Gul. "Nano-Technological Approach towards Anti-Viral Therapy." Global Immunological & Infectious Diseases Review I, no. I (2016): 12-20. https://doi.org/10.31703/giidr.2016(I-I).02